ConductScience.org, home
Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
API referenceFor AI assistants

Trial · NCT02105974

Adverse events114

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 114

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherNasopharyngitisInfections and infestationsFF/VI 100/25 µg QD49806
otherNasopharyngitisInfections and infestationsVI 25 µg QD48814
otherHeadacheNervous system disordersFF/VI 100/25 µg QD29806
otherHeadacheNervous system disordersVI 25 µg QD19814
seriousAny eventRespiratory, thoracic and mediastinal disordersFF/VI 100/25 µg QD10806
seriousAny eventRespiratory, thoracic and mediastinal disordersVI 25 µg QD19814
seriousChronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disordersFF/VI 100/25 µg QD10806
seriousChronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disordersVI 25 µg QD17814
seriousChronic respiratory failureRespiratory, thoracic and mediastinal disordersFF/VI 100/25 µg QD1806
seriousChronic respiratory failureRespiratory, thoracic and mediastinal disordersVI 25 µg QD0814
seriousEpistaxisRespiratory, thoracic and mediastinal disordersFF/VI 100/25 µg QD0806
seriousEpistaxisRespiratory, thoracic and mediastinal disordersVI 25 µg QD1814
seriousPneumonia aspirationRespiratory, thoracic and mediastinal disordersFF/VI 100/25 µg QD0806
seriousPneumonia aspirationRespiratory, thoracic and mediastinal disordersVI 25 µg QD1814
seriousPneumothoraxRespiratory, thoracic and mediastinal disordersFF/VI 100/25 µg QD0806
seriousPneumothoraxRespiratory, thoracic and mediastinal disordersVI 25 µg QD1814
seriousPulmonary embolismRespiratory, thoracic and mediastinal disordersFF/VI 100/25 µg QD1806
seriousPulmonary embolismRespiratory, thoracic and mediastinal disordersVI 25 µg QD0814
seriousAny eventInfections and infestationsFF/VI 100/25 µg QD6806
seriousAny eventInfections and infestationsVI 25 µg QD7814

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02105974/events

API referenceFor AI assistants